METiS Pharmaceuticals
METiS剂泰医药
METiS Pharmaceuticals (剂泰医药) is an AI-driven pharmaceutical company specializing in drug delivery systems, founded in early 2020 by Caida Lai (赖才达) and a team of MIT-affiliated scientists including Academician Hongmin Chen of the US National Academy of Engineering and Dr. Wenshou Wang . The company was originally incubated by XtalPi (晶泰科技) in 2019 before spinning out independently .
The company positions itself as a pioneer in applying artificial intelligence to pharmaceutical formulation and delivery, combining a proprietary high-throughput experimental platform with AI algorithms and quantum chemistry/molecular dynamics simulations to optimize drug candidates and design nucleic acid delivery systems . Its core technical claims include an LNP nucleic acid delivery system with expression efficiency exceeding industry standards by over tenfold, along with multi-organ targeting capabilities .
METiS completed its angel round in late 2019 led by FreeS Fund (峰瑞资本), with Source Code Capital (源码资本) participating as a follow-on investor; FreeS went on to invest in four consecutive rounds through Series A . In April 2022, the company announced two consecutive funding rounds totaling $150 million, led by PICC Capital and China Life Equity, with follow-on participation from Sequoia China, 5Y Capital, and others . The company listed on the Hong Kong Stock Exchange in May 2026 (7666.HK), raising over HK$2.1 billion in what was then the largest healthcare IPO on the exchange that year .
AI-generated — may contain errors, please verify.
Coverage
Yungang Huang on Maintaining a Steady, Long-Term Tech Investment Pace Through Peaks and Troughs
Source Code Capital's Yungang Huang: The Essential Quality for Entrepreneurs Is a Resilient, Bold Spirit of Exploration
We want to be partners on your entrepreneurial journey.
5Y Talk | How Can Computing and AI Break Through the Traditional Paradigm of Drug Discovery?
Entering the Game, Direction, and the Future.
Galixir, a Source Code Capital portfolio company, raises tens of millions of dollars in funding, with existing investor Source Code Capital continuing to increase its stake
Galixir's technical capabilities are built on sophisticated AI models, enabling end-to-end coverage of drug discovery from hit compounds to preclinical candidates.
Source Code Capital portfolio company Dustess announced the completion of its Series B funding round, with existing shareholder Source Code Capital continuing to increase its stake.
An all-in-one private-domain traffic operations platform that helps enterprises close six major marketing loops and complete their digital transformation.
Source Code Capital portfolio company WeiMai announced the completion of a $100 million Series C+ funding round, with existing shareholder Source Code Capital continuing to increase its stake.
Making healthcare services more accessible, now covering 160+ cities across China with deep partnerships with 1,000 public hospitals nationwide.
Source Code Capital portfolio company METiS Pharmaceuticals announced the completion of angel+ and Pre-A funding rounds totaling over 100 million yuan, with existing investor Source Code Capital continuing to increase its stake.
It was the first to propose building an AI-driven formulation development platform, jointly advancing new formulation drugs to clinical trials.
AI-powered pharmaceutical formulation development company "METiS" announced the completion of a multi-million dollar angel round — Source Code Capital participated as a follow-on investor.
The world's first startup to use AI to drive pharmaceutical formulation development, dedicated to providing drug companies with rapid, precise intelligent formulation R&D through high-throughput formulation platforms and AI computing technologies.
